Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
172 hedge funds and large institutions have $2.33B invested in Aerie Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 70 increasing their positions, 53 reducing their positions, and 24 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 53
2% more capital invested
Capital invested by funds: $2.29B → $2.33B (+$41.7M)
4% less funds holding
Funds holding: 179 → 172 (-7)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
27% less call options, than puts
Call options by funds: $15.7M | Put options by funds: $21.5M
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$67.1M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$40.6M |
| 3 |
O
OrbiMed
New York
|
+$31M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$30M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
-$11.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$5.08M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$4.86M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$4.68M |
AERI Hedge Fund Activity: Q1 2018 in Review
172 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2018, worth a combined $2.33B — up 1.8% from $2.29B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AERI and 18 opened new positions — a net loss of 6 holders — while 53 trimmed existing stakes and 70 added.
The largest buyer was HealthCor Management, opening a new position worth an estimated $67.1M. The largest seller was Senzar Asset Management, cutting an estimated $11.6M.
- 172 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2018, down from 179 in Q4 2017.
- Funds reported $2.33B of Aerie Pharmaceuticals stock for Q1 2018, up 1.8% quarter-over-quarter.
- 18 funds opened new Aerie Pharmaceuticals positions in Q1 2018 and 24 closed out, a net change of -6 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2018 was HealthCor Management, an estimated $67.1M added.
- The largest Aerie Pharmaceuticals seller in Q1 2018 was Senzar Asset Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q1 2018.